Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Han, Y., et al
A practical quality checklist should include: Verify that the material is labeled for research use only
NICE technology appraisal guidance TA875 supports the use of semaglutide 2.4 mg (Wegovy) for adults who meet specific criteria: BMI 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, or obstructive sleep apnoea) BMI 3034.9 kg/m in certain higher-risk groups For people from certain ethnic backgrounds including South Asian, Chinese, other Asian, Middle Eastern, Black African, and African-Caribbean groups lower BMI thresholds apply (typically approximately 2.5 kg/m lower than standard thresholds), in line with NHS and NICE guidance on ethnicity-related metabolic risk Treatment must be delivered as part of a specialist weight management service providing multidisciplinary support Treatment duration under TA875 is limited to a maximum of 2 years Should retatrutide receive regulatory approval and a positive NICE appraisal, it is likely that similar eligibility criteria would apply, potentially with additional considerations given its more potent mechanism of action
High blood sugar levels can lead to complications of diabetes
US$ 22.42
US$ 21.29
US$ 23.68
US$ 29.32
US$ 27.12
US$ 29.33
